Literature DB >> 18207067

The role of antiphospholipid syndrome in cardiovascular disease.

Brian R Long1, Ferdinand Leya.   

Abstract

The antiphospholipid syndrome (APS) is associated with various cardiovascular manifestations. These include accelerated atherosclerosis, valvular heart disease, intracardiac thrombi, myocardial and pericardial involvement, cerebral and peripheral vascular disease, and premature restenosis of vein grafts and coronary stents. This article reviews the prevalence and proposed mechanisms of the various cardiovascular diseases associated with APS. It concludes with a discussion of current recommendations for treatment of these conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18207067     DOI: 10.1016/j.hoc.2007.10.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  8 in total

1.  Anti-β2 glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2' and glycoprotein I bα.

Authors:  Wenjing Zhang; Fei Gao; Donghe Lu; Na Sun; Xiaoxue Yin; Meili Jin; Yanhong Liu
Journal:  Front Med       Date:  2015-11-30       Impact factor: 4.592

Review 2.  Difficult clinical situations in the antiphospholipid syndrome.

Authors:  Renata Ferreira Rosa; Michelle Remião Ugolini-Lopes; Audrey Krüse Zeinad-Valim; Elbio D'Amico; Danieli Andrade
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

3.  Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice.

Authors:  Victoria Ulrich; Eddy S Konaniah; Wan-Ru Lee; Sadiksha Khadka; Yu-Min Shen; Joachim Herz; Jane E Salmon; David Y Hui; Philip W Shaul; Chieko Mineo
Journal:  J Am Heart Assoc       Date:  2014-10-14       Impact factor: 5.501

4.  Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.

Authors:  Sangeetha Ramesh; Craig N Morrell; Cristina Tarango; Gail D Thomas; Ivan S Yuhanna; Guillermina Girardi; Joachim Herz; Rolf T Urbanus; Philip G de Groot; Philip E Thorpe; Jane E Salmon; Philip W Shaul; Chieko Mineo
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

Review 5.  Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome.

Authors:  Sonja Praprotnik; Dusan Ferluga; Alenka Vizjak; Anastazija Hvala; Tadej Avcin; Blaz Rozman
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

6.  Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.

Authors:  Wojciech Plazak; Krzysztof Gryga; Hanna Dziedzic; Lidia Tomkiewicz-Pajak; Malgorzata Konieczynska; Piotr Podolec; Jacek Musial
Journal:  Arthritis Res Ther       Date:  2011-07-20       Impact factor: 5.156

Review 7.  Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form.

Authors:  Tamara Kolitz; Shachaf Shiber; Itzhak Sharabi; Asher Winder; Gisele Zandman-Goddard
Journal:  Front Immunol       Date:  2019-05-10       Impact factor: 7.561

Review 8.  Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.

Authors:  Jason S Knight; Yogendra Kanthi
Journal:  Semin Immunopathol       Date:  2022-02-04       Impact factor: 11.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.